APIE Therapeutics Prepares to Advance Pipeline Programs with Appointment of Robert Willette, Ph.D. as Chief Scientific Officer
APIE Therapeutics appoints Robert Willette, Ph.D. to the newly created role of chief scientific officer.
Diane K. Jorkasky, M.D. FACP brings over three decades of experience in all stages of clinical development to the APIE Therapeutics board.
The agreement advances APIE Therapeutics’ pursuit of a treatment for idiopathic pulmonary fibrosis, a rare lung disease